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The daily dose of cydosporine required to attain a desired blood level can vary greatly among patients.
Because elimination of cyclosporine depends on its metabolism in the liver by an enzyme (cytochrome P-
450IIIA) that also demethylates erythromycin, we reasoned that the ability of patients to demethylate a
test dose of erythromycin might be useful in estimating their appropriate daily doses of cydosporine.
Accordingly, the ['4C-N-methyl] erythromycin breath test was administered to 32 patients before they
received 3.0, 5.0, or 7.5 mg/kg/day cyclosporine to treat psoriasis. We found that a simple mathematical
equation incorporating just the "CO2 production, the age of the patient, and the daily dose of cyclosporine
accounted for almost 80% (R2 = 0.78) of the interpatient variability in cyclosporine blood levels we
observed. Our data indicate that P-450111A activity largely accounts for the relationship between dose
of cydosporine and blood levels for an individual patient. We conclude that the erythromycin breathtest
may be a convenient guide for cydosporine dosing. (CLIN PHARMACOL THER 1990;48:120-9.)
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Cyclosporine, an immunosuppressive drug widely
used to prevent allograft rejection in transplant recipi-
ents, appears to be useful in the treatment of many
common autoimmune diseases (reviewed by Bachl).
More than 5000 patients are currently receiving cyclo-
sporine for autoimmune diseases, which represents a
small fraction of the persons that may benefit from this
drug. Enthusiasm for the therapeutic effects of cyclo-
sporine has been tempered, however, by the high in-
cidence of side effects associated with cyclosporine
treatment, particularly renal dysfunction and hyperten-
sion (reviewed by Myers).2
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In an attempt to limit toxicity while maximizing the
therapeutic effects of cyclosporine, blood levels are usu-
ally closely monitored for at least several weeks after
patients begin treatment with cyclosporine, and the
daily dose is adjusted to achieve a trough blood level
within a relatively narrow range.' This is often a te-
dious and costly process because the daily dose of cy-
closporine required to achieve a target blood level can
vary at least 10-fold among patients.' Thus an empirical
initial dose of cyclosporine will produce either poten-
tially subtherapeutic or potentially toxic blood levels in
many patients. Furthermore, because cyclosporine has
a relatively long elimination half-life in blood,' it may
take many days or weeks to arrive at an appropriate
cyclosporine dosing regimen for some patients. To bet-
ter estimate individual dosing requirements, cyclospo-
rine pharmacokinetics are routinely determined in each
patient before cyclosporine therapy in some medical
centers." These studies take several days to perform
and have not become a standard practice.
It has recently been discovered that the elimination
of cyclosporine from the body depends on its metab-
olism in the liver by cytochrome P-450111A,10." a phase
1 enzyme whose catalytic activity varies manyfold
among patients. Because P-450IIIA also catalyzes
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the N-demethylation of erythromycin,' we reasoned
that the ability of a patient to demethylate erythromycin
might be useful in predicting an appropriate initial
dosing regimen for cyclosporine. This was an espe-
cially attractive idea because studies in rats and in
human patients indicate that hepatic erythromycin N-
demethylase (P-450IIIA) activity can be measured as
the production of breath 'CO, after intravenous injec-
tion of ['4C-N-methyl]erythromycin.' This test requires
no special expertise or equipment to perform, and the
results could be available in most institutions within
hours. 14
We therefore administered the breath test to 32 pa-
tients scheduled to receive cyclosporine to treat pso-
riasis. We found that, for most patients studied, the
steady-state cyclosporine blood level could be accu-
rately predicted by a simple equation incorporating the
breath test result, the age of the patient, and the dose
of cyclosporine received.
MATERIAL AND METHODS
Patients and treatment. Patients enrolled in this
study were selected from 85 patients with recalcitrant
psoriasis who were scheduled to receive varying doses
of oral cyclosporine in an otherwise unrelated study.
Both the psoriasis treatment and the breath test proto-
cols had been approved by the institutional review
board of the University of Michigan Medical Center
(Ann Arbor, Mich.). Consent was obtained in writing
from each patient after the nature and procedures of the
study had been explained. The study population was in
good general health, and the entrance criteria included
renal function (BUN, creatinine, 24-hour creatinine
clearance) and liver chemistries (bilirubin, aspartate
aminotransferase, alanine aminotransferase, albumin,
and alkaline phosphatase) that were within 15% of the
normal range.
At the time of enrollment, each patient was assigned
a consecutive number that had been randomly assigned
to a specific treatment group before the start of the
study. Patients received placebo (vehicle alone) or 3.0,
5.0, or 7.5 mg /kg cyclosporine daily without knowl-
edge of their dosing assignments. All patients were
instructed to take their medications as a single dose
before noon each day. On the days of their clinic visits,
all patients were instructed to take their doses after
"trough" blood levels were obtained. Patients were not
routinely questioned regarding medication compliance
unless a blood level greater than 400 ng / ml was ob-
tained. In that case, patients were contacted and ques-
tioned about compliance by phone.
Enrollment in our study was initially limited to 30
patients in accordance with regulations of the Food and
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Table I. Descriptive measures of predictor
variables used in modeling steady-state
cyclosporine blood levels
n = 32.
*% 14C exhaled in 1 hour.
tSerum.
Drug Administration concerning radiopharmaceuticals
administered under an institutional Investigational New
Drug (IND) designation. For this reason, an investigator
(C.N.E.) who was unblinded to the treatments ran-
domly selected patient numbers from each treatment
group before the project began; the placebo and 3
mg /kg / day groups received fewer assignments. Before
completion of the study, an individual IND was ob-
tained for the erythromycin breath test. This enabled
us to study each of the last seven patients enrolled in
the psoriasis study, resulting in a total of 34 entered
patients. The breath tests were performed and analyzed
without knowledge of the daily cyclosporine dose that
each patient was scheduled to receive. Data from one
patient had to be discarded because of a laboratory error
resulting in an uninterpretable initial breath test result.
In another patient, all cyclosporine blood levels (a total
of three) had to be discarded because of poor compli-
ance. Characteristics and selected demographics of the
32 remaining patients are shown in Table I. Seven pa-
tients were women. Eight patients were receiving med-
ications to control blood pressure; however, no changes
in their regimens were made during the study interval.
The remaining 24 patients did not receive systemic
medications other than cyclosporine.
Laboratories. Trough cyclosporine blood levels were
obtained in all patients after week 1 and week 2 of
cyclosporine treatment and every 2 weeks thereafter.
Additional blood levels were obtained in some patients
when past values were greater than 400 ng / ml. Cyclo-
sporine levels were determined in whole blood by
HPLC. Serum triglycerides, total cholesterol, and
Pretherapy
variable Minimum Maximum Mean SD
Breath test* 1.39 4.56 2.51 0.75
Weight (kg) 64.0 116.0 85.8 13.4
Age (yr) 19 67 43.8 13.2
Body surface
area (m2)
1.55 2.40 2.01 0.20
HDL cholesterol
(mmol/L)f
0.70 2.20 1.16 0.31
LDL cholesterol
(mmol/L)f
2.23 5.41 3.58 0.74
Total cholesterol
(mmol/L)f
3.98 7.16 5.51 0.88
Triglycerides
(mmol/L)f
0.50 3.22 1.69 0.82
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Fig. 1. Blood levels of cyclosporine observed in patients
receiving each dose. Each line connects the cyclosporine
blood levels for an individual patient.
high density lipoprotein (HDL) cholesterol levels
were determined by commercial automated systems
(METPATH). Low density lipoprotein (LDL) cho-
lesterol levels were estimated as follows: Total choles-
terol (HDL + triglycerides / 5).
Erythromycin breath test. Of the 32 patients studied,
30 received the erythromycin breath test within 3 weeks
before starting cyclosporine treatment and two patients
were tested approximately 16 weeks before receiving
cyclosporine (these patients were initially randomized
to receive placebo (vehicle) and were subsequently
switched to 3 mg /kg/ day). Each patient was retested
after 1 and 4 weeks of treatment with cyclosporine.
The breath test was administered during scheduled
clinic visits, immediately after blood samples for cy-
closporine were taken and before the patients took their
daily dose of cyclosporine. Each patient was intrave-
nously injected with 3 pLCi (0.074 limo') of r4C-N-
methyllerythromycin (Du Pont New England Nuclear
Research Products, Boston, Mass.) dissolved in 2.5 ml
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of 5% dextrose in water according to a previously pub-
lished protocol:4 At timed intervals during the next
hour, the patient was asked to exhale through a tube,
creating bubbles in a solution of 4 ml hyamine hy-
droxide (Sigma Chemical Co. , St. Louis, Mo.) and
ethanol (1: 1) that contained a trace amount of thy-
molphthalein. Patients were instructed to blow bubbles
until the blue color vanished, at which point 2 mmol
CO2 had been trapped. Twelve milliliters of Aquasol
solution (New England Nuclear Research Products) was
then added to each vial, and the specific content of
carbon 14 was determined by scintillation counting. The
percentage of administered carbon 14 exhaled per min-
ute was calculated at each time point on the basis of
an endogenous production of carbon dioxide of 5 mmol
CO2/ m2 body surface area' and was plotted as a func-
tion of time after injection. The resulting area under
the curve estimates the percentage of injected carbon
14 exhaled in breath during the first hour after in-
jection.'
Statistical analysis. For each patient, the mean of all
cyclosporine blood levels obtained after the first week
of therapy was determined. Because many patients re-
quired dosage adjustments before completion of the
study, only blood levels obtained while they were re-
ceiving the original assigned dosages were considered
(Fig. 1). The mean duration of treatment at the initial
dose was 11 weeks. Three individual values were dis-
carded from analysis in two patients because there was
chart documentation that these patients had erroneously
taken the cyclosporine dose on the morning of their
clinic visit. Multiple regression analysis by the least-
squares method'7 was used to construct models for pre-
dicting the mean cyclosporine levels from variables de-
termined before therapy. Before the regression analysis,
the mean blood levels of cyclosporine were converted
to their logarithms (base 10) because this reduced the
heterogeneity of variances betveen the dosage groups.
A predictor variable was retained in the model if the
associated two-tailed p value was less than or equal to
the 0.05 level of significance. The analyses were per-
formed with the use of MIDAS (Michigan Interactive
Data Analysis System), a statistical software package
developed by the Statistical Research Laboratory at the
University of Michigan.
RESULTS
Production of CO2 from erythromycin and cy-
closporine blood levels. There was a severalfold
range in the production of '4CO2 from ['4C-N-
methyl]erythromycin, determined before therapy in the
32 patients studied (Table I). This is comparable to the
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range of values obtained in patients hospitalized with
a variety of illnesses.' After the code was broken, it
was determined that six patients had received 3.0
mg/kg /day cyclosporine, 14 patients had received
5.0 mg/kg /day cyclosporine, and 12 patients had re-
ceived 7.5 mg/kg/day cyclosporine.
The blood levels of cyclosporine for all but one pa-
tient increased between week 1 and week 2 of cyclo-
sporine therapy; however, there was no clear upward
or downward trend in blood levels after 2 weeks of
therapy (Fig. 1). To minimize random variations in
blood levels, the mean of all blood level measurements
obtained after week 1 was determined for each patient
and used in subsequent analyses. There was significant
variability in the mean blood levels among individuals
receiving the identical dose of cyclosporine, and the
distribution of values within each group did not appear
to be normal (Fig. 2). Nevertheless, there was an in-
verse correlation between the production of CO, from
erythromycin and the mean blood levels of cyclosporine
in the patients in each treatment group (Fig. 3):
for those receiving 3 mg /kg/day, r --.-- 0.83; 5
mg /kg /day, r = 0.61; and 7.5 mg /kg /day, n =
0.70. The correlation was statistically significant at
each dose level ( p < 0.05). Logarithmic transformation
of the mean cyclosporine levels reduced the heteroge-
neity of variances between the groups and increased
the symmetry within each group (data not shown) and
also improved the correlations with the breath test re-
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Fig. 2. Mean blood levels of cyclosporine observed at each dose. Each point represents the mean
cyclosporine level of one patient. The small horizontal bars indicate the mean for each group;
wider bars indicate 1 SEM.
sults: r = 0.88 for 3 mg/kg/day; r = 0.64 for 5
mg/kg /day; and n = 0.70 for 7.5 mg /kg/day. The
strong correlations indicate that differences in eryth-
romycin demethylase (P-450IIIA) activity largely ac-
counted for interpatient variation in cyclosporine blood
levels at each dose.
Construction of a predictive model. We next inves-
tigated whether the results of the erythromycin breath
test could be incorporated into a mathematical model
capable of predicting, for each individual, the cyclo-
sporine blood levels we observed. We also wanted to
determine if other patient characteristics and widely
available blood chemistries (Table I) might add to the
predictive capacity of the model. The demographic vari-
ables listed in Table I were included in our analysis
because some studies have suggested that they may
influence cyclosporine pharmacokinetics."-" The influ-
ence of plasma lipid fractions was also assessed because
cyclosporine appears to exist in blood largely bound to
lipoproteins and uptake of cyclosporine by the liver may
depend in part on lipoprotein receptors.' We simulta-
neously analyzed the data from all 32 patients using a
stepwise, multiple regression method. The logarithm of
the mean cyclosporine level was taken as the dependent
variable, and cyclosporine dosage, patient gender,
weight, body surface area, age, and pretherapy values
for the erythromycin breath test result, serum HDL
cholesterol, LDL cholesterol, total cholesterol, and tri-
glycerides were taken as independent, or predictor, van-
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ables. This statistical approach examines all predictor
variables simultaneously and, in the initial regression
step, selects the single variable with the highest cor-
relation with the logarithms of the blood levels of cy-
closporine. A mathematical equation, or "model," is
then generated that best estimates the log cyclosporine
blood level as a function of the selected variable. At
each subsequent regression step, the partial correlations
(R) of unselected variables are calculated on the basis
of the model that includes the variable(s) already in-
corporated. The most predictive variable is then incor-
porated into the model if its predictive value is statis-
tically significant (p < 0.05). The predictive accuracy
of the model created at each step is assessed by the
coefficient of multiple determinations, or R2.'7
As shown in Table II, dose was the predictive vari-
able selected in the first regression step. Dose was pos-
itively correlated with log cyclosporine blood level as
expected (R = 0.68). However, the model incorporat-
o
2 3 4 5
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(%C-14 exhaled / hr)
Fig. 3. Correlation between the erythromycin breath test result and mean cyclosporine blood levels.
Each point represents the mean cyclosporine blood level and the erythromycin breath test result
(ERMBT) obtained in a single patient. Symbols denote the dosages of cyclosporine each patient
received: triangles, 3.0 mg/kg/day; circles, 5.0 mg/kg/day; squares, 7.5 mg/kg/day.
ing dose alone accounted for less than one half of the
interpatient variability observed (R2 = 0.47).
After differences in assigned dosages of cyclosporine
were taken into account, the erythromycin breath test
result had the highest predictive value of the remaining
variables (Table II, step 2). Variables that were also
significantly predictive (p < 0.05) were patient age,
weight, and HDL cholesterol (Table II, step 2). Neg-
ative correlations were observed with LDL cholesterol
and total cholesterol, but these did not attain statistical
significance. The breath test result was therefore se-
lected in the second regression and the model containing
dose and the breath test result accounted for 72% of
the interpatient variability observed (R2 = 0.72) (Table
II, step 2).
Patient age was the only variable that remained pre-
dictive after dose and the breath test result were incor-
ported into the model (Table II, step 3). Body weight
no longer contributed to the predictive capacity of the
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Table II. Suirunary of the stepwise selection
procedure used in creating a multiple regression
model capable of predicting the logarithm of
the observed mean cyclosporine blood level
*Variables are listed at each regression step in rank order of predictive
capacity. The variable in italics was selected to be incorporated into the model
at that step.
t Partial correlation coefficient.
Coefficient of multiple determinations reflecting the predictive capacity of
the model after incorporation of the variable selected at that step.
model; this was because there was a significant negative
correlation between body weight and the breath test
result (r = -0.44, p = 0.01). The predictive capac-
ity of the model was also not improved at this step by
incorporating HDL cholesterol because it correlated
with the breath test result (r = 0.62, p < 0.001). Pa-
tient age was therefore incorporated in the third regres-
sion step, which resulted in a slight improvement in
the predictive capacity of the model (R2 = 0.78; Table
II, step 3). The model was not significantly improved
by additional regressions incorporating the other vari-
ables (data not shown). The following mathematical
equation (Table III) was derived from our analysis:
log (cyclosporine blood level, ng/ml) =
1.7 + 0.099(dose, mg/kg/day) -
0.157(breath test, %eV) + 0.0055(age,years)
A comparison of the cyclosporine blood levels pre-
dicted by this model and those actually observed in
each of our patients is shown in Fig. 4. The observed
blood levels were within 50 ng / ml of that predicted by
our model in 26 of the 32 patients (81%).
Breath test results at week I and 4. After 1 week
of therapy with cyclosporine, there was a 20% decrease
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Table III. Parameters of the final model*
*Log (cyclosporine) = 1.7 + 0.099(dose) - 0.157(breath test) +
0.0055(age)
in the mean breath test value, from 2.64% to 2.11%,
when all patients were considered. This decrease was
statistically significant (p < 0.0001 as determined by
a paired t test) and the percent decrease in the breath
test result correlated with the cyclosporine blood level
determined at week 1 (r = 0.42, p = 0.05). The mean
breath test value did not change significantly between
weeks 1 and 4 of treatment (2.11% and 2.13%, re-
spectively).
We next asked whether our model was valid for
breath test results obtained while patients were receiv-
ing cyclosporine. We therefore repeated our multiple
regression analysis, substituting the breath test values
obtained after each patient had received cyclosporine
for 4 weeks (data not shown). The resulting equation
was almost identical to the equation obtained with the
pretherapy breath test results (Table III):
log (cyclosporine blood level, ng/ml) =
1.64 + 0.093(dose,mg/kg/day -
0.137(breath test, %14C) + 0.0054(age,years)
The predictive accuracy of this equation (R2 = 0.75)
was also comparable to the predictive accuracy of the
model that was based on the initial breath test results.
DISCUSSION
Our data indicates that liver erythromycin N-
demethylase (P-450IIIA) activity largely accounts for
the relationship between the dose of cyclosporine and
the blood levels for an individual patient. After differ-
ences in dose of cyclosporine were considered, the
breath test result was the most predictive of the variables
we examined (Table II, step 2). Indeed, our model
incorporating just dosage and the breath test result ac-
counted for 72% of the interpatient variability in the
logarithms of the cyclosporine blood levels we observed
(Table II, step 2). We also noted a significant positive
correlation between the logarithms of the cyclosporine
blood levels and patient weight, and this has been re-
ported by others.' Our finding that the logarithms of
the cyclosporine blood levels correlated with HDL cho-
lesterol has not been previously reported, to our
Step Variable* Rt p Value
Cumulative
I Dosage 0.68 <0.00005 0.47
2 Breath test -0.68 <0.00005 0.72
Age 0.486 0.0056
Weight 0.38 0.034
HDL cholesterol -0.38 0.034
Triglycerides 0.24 0.20
Total cholesterol -0.18 0.31
LDL cholesterol -0.19 0.31
Body surface area 0.18 0.33
Gender -0.049 0.79
3 Age 0.48 0.0074 0.78
Triglycerides 0.19 0.31
Gender -0.18 0.34
Weight 0.13 0.50
Body surface area 0.065 0.73
LDL cholesterol -0.044 0.82
HDL cholesterol 0.039 0.84
Total cholesterol -0.037 0.85
Constant 1.700 0.130 <0.00005
Dose (mg/kg/day) 0.099 0.0145 <0.00005
Pretherapy breath test -0.157 0.032 <0.00005
(% ''C exhaled in 1 hr)
Age (yr) 0.0055 0.0019 <0.0074
Variable Coefficient SEM p Value
1000
0 '10 20 30 ' 0 00 400
B Observed CsA Levels
(ng/ml)
Fig. 4. Comparison of predicted and observed levels of cyclosporine. For each patient, the predicted
cyclosporine blood level was derived by the mathematical model (Table III) and compared with
the mean cyclosporine blood level actually observed. A, Logarithmic plot (R2 = 0.78). B, Linear
plot (122 = 0.68). Symbols denote the dosages each patient received: triangles, 3.0 mg/kg/day;
circles, 5.0 mg/kg/day; squares, 7.5 mg/kg/day.
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knowledge. We found, however, that the predictive ca-
pacities of weight and HDL cholesterol were lost after
incorporating the breath test results into our model
(Table II, step 3). This was because there was a sig-
nificant negative correlation between patient weight and
the breath test result and a significant positive corre-
lation between HDL cholesterol and the breath test re-
sult. In a given individual, therefore, the logarithm of
the cyclosporine blood levels were partially predicted
by body weight and HDL cholesterol because these
parameters partially predicted P-45011IA activity. Of
the remaining variables, only patient age was a signif-
icant predictor, and the positive correlation that we
found was consistent with other reports that suggested
that elderly patients require less cyclosporine.' Unlike
patient weight and HDL cholesterol, the predictive ca-
pacity of patient age was not lost after incorporation of
the breath test results into the model (Table II, step 3).
This indicates that the influence of patient age on cy-
closporine blood levels was independent of P-45011IA
activity, and we have not observed a consistent effect
of aging on liver P-45011IA activity in the more than
140 patients examined to date (Watkins PB, unpub-
lished observations, March 1990).
We have previously reported that the erythromycin
breath test results are significantly higher in women
than in men, 14 and this has been confirmed in the more
than 140 patients who have received the breath test to
date (Watkins PB, unpublished observations, March
1990). The clearance of cyclosporine has also been
reported to be more rapid in women than in men:8
Gender had no predictive value in our model, however,
and this presumably reflects the relatively small number
of women studied. In aggregate, our data suggests that
women may require less cyclosporine than men to attain
target blood levels.
We also found that the breath test values of the pa-
tients decreased an average of 20% after they started
therapy with cyclosporine, and that the decrease ob-
served in each individual correlated with the cyclospo-
rine blood level determined at the time the breath test
was performed. This was an expected finding because
both cyclosporine and the test dose of erythromycin
should compete for in vivo binding to, and metabolism
by, liver P-45011IA. The 20% mean decrease in breath
test results was modest compared with the severalfold
interpatient variation in this parameter; this is why the
model generated by the multiple regression analysis was
almost identical whether we used the results from the
pretherapy or week 4 breath test. The fact that the breath
test values of the patients did not significantly change
between week 1 and week 4 of therapy suggests that
liver P-45011IA is not induced or inhibited by prolonged
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treatment with cyclosporine. This probably explains
why the model based on just the initial breath test value
appeared to have predictive value during the duration
of our study.
Several factors probably account for the 22% vari-
ability in cyclosporine blood levels not accounted for
by our model. First, it is likely that imperfect compli-
ance went undetected in at least some patients in our
study because compliance with the dosing regimen was
checked only in patients whose blood levels exceeded
400 ng /ml. This is a likely explanation for wide in-
trapatient variation in cyclosporine blood levels that
was especially evident in the patients receiving 7.5
mg/kg /day of the drug (Fig. 1). Second, studies in
rats have suggested that the breath test can detect small
changes in P-450IIIA catalytic activity only when phar-
macologic doses of erythromycin are administered
along with the radiolabeled compound:4 The use of
trace doses of erythromycin in our study may therefore
have resulted in some inaccuracy in determining P-
45011IA activity. Finally, interpatient differences in gut
absorption of cyclosporine are likely to have existed in
our population.22'" Indeed, the very high predictive ca-
pacity of our model appears to contradict evidence that
suggests that cyclosporine blood levels largely reflect
the extent of absorption of the drug."'" However, in-
terpatient differences in the bioavailability of cyclo-
sporine may be accounted for, in part, by the eryth-
romycin breath test result. This is because P-450IIIA
is present in human jejunal mucosa24 where metabolism
of cyclosporine by the enzyme might appear as incom-
plete oral absorption in a pharmacokinetic study. If the
catalytic activity of intestinal P-450111A mirrors that of
the liver in a given individual, both would be reflected
in the breath test result. We have recently proved that
cyclosporine is metabolized by intestinal P-450IIIA in
rats," and similar studies are now underway in human
tissue.
Our data strongly suggest that the erythromycin
breath test will provide useful information in indivi-
dualizing at least the initial dosing of cyclosporine.
Only three patients had differences between predicted
and observed blood levels of more than 100 ng / ml
(Fig. 4, B). Two of these patients were men receiving
7.5 mg /kg /day cyclosporine, and compliance was sus-
pect in each of these subjects. One had two blood levels
discarded because of documented improper dosing, and
the other was the patient shown in Fig. 1 whose con-
secutive blood levels repeatedly varied in excess of 350
ng /ml. The remaining patient was a man receiving 5
mg /kg /day cyclosporine, and he appeared to be com-
pliant. He had the highest mean cyclosporine blood
levels in this treatment group (Fig. 1), and he had the
128 Watkins et al.
lowest breath test result of any patient studied (1.39%
of administered "C exhaled per minute). Thus, al-
though our model did not work well for this patient,
his very low breath test results supports our hypothesis
that interpatient differences in P-45011IA activity
largely explain the heterogeneous dosing requirements
characteristic of the drug.
It is important to note that the actual mathematical
model generated by our data may not be useful in other
patient populations for several reasons. First, the pa-
tients we studied were receiving a relatively narrow
range of daily doses of cyclosporine and the equation
may therefore not apply to patients receiving other
doses. For example, a 60-year-old man with an average
breath test result of 2.5% (Table I) is predicted by our
model (Table III) to have a cyclosporine blood level of
46 ng / ml when he is not even receiving the drug
(dose =-- 0). Second, the patients we studied were gen-
erally healthy and psoriasis has no known effects on
hepatic, intestinal, or renal handling of drugs. In con-
trast, the majority of patients currently receiving cy-
closporine are organ transplant recipients who often
have varying degrees of liver, intestinal, or renal dys-
function. Moreover, organ transplant recipients usually
receive varying doses of steroids that are known in-
ducers of P-450IIIA. 14'26 It therefore seems unlikely that
a single breath test result will remain predictive over
time in these patients. Finally, different methods for
measuring parent cyclosporine are used at different
institutions, and the results are not always standardized.
Our study illustrates the potential clinical usefulness
of tests capable of measuring the activity of individual
liver cytochromes P-450. It has recently been appre-
ciated that inherited defects are common in at least some
hepatic cytochromes P-450 and that "poor metaboliz-
ers" may require reduced daily doses of some medi-
cations.' The situation is more complex with P-450IIIA
where there appears to be a broad unimodal distribution
of enzyme activity in the population, and a distinct
subpopulation with a poor metabolizer phenotype has
not been identified.' Our study is novel in that it rep-
resents the first attempt to use a measurement of a
cytochrome P-450 activity (the erythromycin breath
test) in a mathematical model that may be useful in
estimating appropriate dosing for the majority of pa-
tients receiving a drug. As noninvasive assays of other
cytochromes P-450 become available, we predict that
they may also serve as useful guides in the dosing of
many other drugs.
In summary, our data suggest that at a given daily
dose of cyclosporine, an individual's trough blood level
of the drug can be predicted by use of just two param-
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eters: the erythromycin breath test result and the age of
the patient. It should now be possible to adapt the breath
test to use the nonradioactive isotope carbon 13.29 Fu-
ture studies will determine whether the erythromycin
breath test also predicts blood levels of other drugs now
known to be extensively metabolized by P-45011IA,
including nifedipine' and sex hormones .1230
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